{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:35:45Z","timestamp":1766068545098,"version":"3.48.0"},"reference-count":39,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"publisher","award":["Agreement #075-15-2025-526"],"award-info":[{"award-number":["Agreement #075-15-2025-526"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>West Nile fever is an infectious disease caused by the West Nile virus (WNV), which is transmitted by mosquitoes. Epidemiological surveillance confirms the potential risk of WNV infection in human populations. The lack of specific antiviral therapeutics and vaccines against WNV underscores the urgent need to develop effective therapeutic approaches. In this study, a recombinant chimeric monoclonal antibody (mAb) 900 was generated based on the broadly neutralizing and protective murine mAb 9E2. The antigen-binding regions of the murine mAb were fused with the constant domains (CH2\u2013CH3) of human IgG1. Two key amino acid clusters, M252\/S254\/T256 and H433\/N434, were introduced into the CH2\u2013CH3 domains to enhance the affinity of mAb 900 for the neonatal Fc receptor (FcRn). The engineered mAb 900 was produced in CHO cells and purified to high homogeneity. Biophysical characterization confirmed its stability and correct dimeric assembly. Comparative analysis demonstrated that mAb 900 retained the high antigen-binding affinity and potent virus-neutralizing activity of its murine predecessor. Most importantly, mAb 900 demonstrated significant protective efficacy in a lethal mouse model of WNV infection. These results establish the proof of concept for mAb 900 as a promising candidate for further preclinical development against WNV infection.<\/jats:p>","DOI":"10.3390\/ijms262412181","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:32:03Z","timestamp":1766068323000},"page":"12181","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Does the Chimerization Process Affect the Immunochemical Properties of WNV-Neutralizing Antibody 900?"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4085-2887","authenticated-orcid":false,"given":"Anastasiya A.","family":"Isaeva","sequence":"first","affiliation":[{"name":"State Scientific Center of Virology and Biotechnology \u201cVector\u201d, Rospotrebnadzor, 630559 Koltsovo, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1091-3586","authenticated-orcid":false,"given":"Valentina S.","family":"Nesmeyanova","sequence":"additional","affiliation":[{"name":"State Scientific Center of Virology and Biotechnology \u201cVector\u201d, Rospotrebnadzor, 630559 Koltsovo, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniil V.","family":"Shanshin","sequence":"additional","affiliation":[{"name":"State Scientific Center of Virology and Biotechnology \u201cVector\u201d, Rospotrebnadzor, 630559 Koltsovo, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikita D.","family":"Ushkalenko","sequence":"additional","affiliation":[{"name":"State Scientific Center of Virology and Biotechnology \u201cVector\u201d, Rospotrebnadzor, 630559 Koltsovo, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina A.","family":"Volosnikova","sequence":"additional","affiliation":[{"name":"State Scientific Center of Virology and Biotechnology \u201cVector\u201d, Rospotrebnadzor, 630559 Koltsovo, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9006-8313","authenticated-orcid":false,"given":"Tatiana I.","family":"Esina","sequence":"additional","affiliation":[{"name":"State Scientific Center of Virology and Biotechnology \u201cVector\u201d, Rospotrebnadzor, 630559 Koltsovo, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2782-8364","authenticated-orcid":false,"given":"Elena V.","family":"Protopopova","sequence":"additional","affiliation":[{"name":"State Scientific Center of Virology and Biotechnology \u201cVector\u201d, Rospotrebnadzor, 630559 Koltsovo, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2729-0592","authenticated-orcid":false,"given":"Victor A.","family":"Svyatchenko","sequence":"additional","affiliation":[{"name":"State Scientific Center of Virology and Biotechnology \u201cVector\u201d, Rospotrebnadzor, 630559 Koltsovo, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0229-321X","authenticated-orcid":false,"given":"Valery B.","family":"Loktev","sequence":"additional","affiliation":[{"name":"State Scientific Center of Virology and Biotechnology \u201cVector\u201d, Rospotrebnadzor, 630559 Koltsovo, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey E.","family":"Olkin","sequence":"additional","affiliation":[{"name":"State Scientific Center of Virology and Biotechnology \u201cVector\u201d, Rospotrebnadzor, 630559 Koltsovo, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena D.","family":"Danilenko","sequence":"additional","affiliation":[{"name":"State Scientific Center of Virology and Biotechnology \u201cVector\u201d, Rospotrebnadzor, 630559 Koltsovo, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena I.","family":"Kazachinskaia","sequence":"additional","affiliation":[{"name":"State Scientific Center of Virology and Biotechnology \u201cVector\u201d, Rospotrebnadzor, 630559 Koltsovo, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8023-4453","authenticated-orcid":false,"given":"Dmitriy N.","family":"Shcherbakov","sequence":"additional","affiliation":[{"name":"State Scientific Center of Virology and Biotechnology \u201cVector\u201d, Rospotrebnadzor, 630559 Koltsovo, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Hru\u0161kovicov\u00e1, J., Bhide, K., Petrou\u0161kov\u00e1, P., Tk\u00e1\u010dov\u00e1, Z., Mochn\u00e1\u010dov\u00e1, E., \u010curl\u00edk, J., Bhide, M., and Kulkarni, A. (2022). Engineering the Single Domain Antibodies Targeting Receptor Binding Motifs Within the Domain III of West Nile Virus Envelope Glycoprotein. Front. Microbiol., 13.","DOI":"10.3389\/fmicb.2022.801466"},{"key":"ref_2","first-page":"14","article-title":"Sensitivity Characteristics of Genotype 2 West Nile Virus Strains to Anti-Viral Drugs","volume":"69","author":"Gusev","year":"2024","journal-title":"Antibiot. Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kouroupis, D., Charisi, K., and Pyrpasopoulou, A. (2023). The Ongoing Epidemic of West Nile Virus in Greece: The Contribution of Biological Vectors and Reservoirs and the Importance of Climate and Socioeconomic Factors Revisited. Trop. Med. Infect. Dis., 8.","DOI":"10.3390\/tropicalmed8090453"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Martins, I.C., Ricardo, R.C., and Santos, N.C. (2022). Dengue, West Nile, and Zika Viruses: Potential Novel Antiviral Biologics Drugs Currently at Discovery and Preclinical Development Stages. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14112535"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Mencattelli, G., Ndione, M.H.D., Ros\u00e0, R., Marini, G., Diagne, C.T., Diagne, M.M., Fall, G., Faye, O., Diallo, M., and Faye, O. (2022). Epidemiology of West Nile virus in Africa: An underestimated threat. PLoS Negl. Trop. Dis., 16.","DOI":"10.1371\/journal.pntd.0010075"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.21055\/0370-1069-2024-1-89-101","article-title":"West Nile Fever: Analysis of the Epidemiological Situation in the Russian Federation in 2023, Forecast for 2024","volume":"28","author":"Putintseva","year":"2024","journal-title":"Probl. Osob. Opasnykh Infektsii"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11908-022-00783-4","article-title":"West Nile virus: Another emerging arboviral risk for travelers?","volume":"24","author":"Jani","year":"2022","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.imj.2023.09.001","article-title":"Development and evaluation of neutralizing antibodies for cross-protection against West Nile virus and Japanese encephalitis virus","volume":"2","author":"Yang","year":"2023","journal-title":"Infect. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"20131","DOI":"10.1038\/s41598-021-99696-w","article-title":"Development of peptides targeting receptor binding site of the envelope glycoprotein to contain the West Nile virus infection","volume":"11","author":"Bhide","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100140","DOI":"10.1016\/j.slasd.2024.01.001","article-title":"Developing recombinant antibodies by phage display technology to neutralize viral infectious diseases","volume":"29","author":"Mustafa","year":"2024","journal-title":"SLAS Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"115099","DOI":"10.1016\/j.biopha.2023.115099","article-title":"Exploring the future of SARS-CoV-2 treatment after the first two years of the pandemic: A comparative study of alternative therapeutics","volume":"165","author":"Babalola","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ormundo, L.F., Barreto, C.T., and Tsuruta, L.R. (2023). Development of Therapeutic Monoclonal Antibodies for Emerging Arbovirus Infections. Viruses, 15.","DOI":"10.20944\/preprints202309.0943.v1"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e1107","DOI":"10.1055\/a-1990-2633","article-title":"Effectiveness and Safety of Palivizumab for the Prevention of Serious Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus: A Systematic Review","volume":"41","author":"Gonzales","year":"2024","journal-title":"Am. J. Perinatol."},{"key":"ref_14","first-page":"100847","article-title":"Safety, efficacy and pharmacokinetics of palivizumab in off-label neonates, infants, and young children at risk for serious respiratory syncytial virus infection: A multicenter phase II clinical trial","volume":"39","author":"Mori","year":"2023","journal-title":"Lancet Reg. Health West. Pac."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/17460441.2020.1714586","article-title":"New avenues for therapeutic discovery against West Nile virus","volume":"15","author":"Sinigaglia","year":"2020","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Pirkalkhoran, S., Grabowska, W.R., Kashkoli, H.H., Mirhassani, R., Guiliano, D., Dolphin, C., and Khalili, H. (2023). Bioengineering of Antibody Fragments: Challenges and Opportunities. Bioengineering, 10.","DOI":"10.3390\/bioengineering10020122"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Gordon, G.L., Raybould, M.I.J., Wong, A., and Deane, C.M. (2024). Prospects for the computational humanization of antibodies and nanobodies. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1399438"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12951-022-01259-2","article-title":"A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies","volume":"20","author":"Hsieh","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wang, Y., Chen, Y.L., Xu, H., Rana, G.E., Tan, X., He, M., Jing, Q., Wang, Q., Wang, G., and Xie, Z. (2024). Comparison of \u2018framework Shuffling\u2019 and \u2018CDR Grafting\u2019 in humanization of a PD-1 murine antibody. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1395854"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Yang, P., Wu, X., Shang, H., Sun, Z., Wang, Z., Song, Z., Yuan, H., Deng, F., Shen, S., and Guo, Y. (2024). Molecular mechanism and structure-guided humanization of a broadly neutralizing antibody against SFTSV. PLoS Pathog., 20.","DOI":"10.1371\/journal.ppat.1012550"},{"key":"ref_21","unstructured":"Kazachinskaja, E.I., Alekseenko, T.P., Razumov, I.A., Protopopova, E.V., and Loktev, V.B. (2005). Strain of Hybrid Cells of Animal Mus musculus L, 9E2, Used in Preparing Monoclonal Antibody to West Nile Virus Protein E of Strain WNV\/LEIV-VIG99-27889. (Patent RU 2 265 658 C2)."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.antiviral.2007.08.010","article-title":"Genetically delivered antibody protects against West Nile virus","volume":"77","author":"Pereboev","year":"2008","journal-title":"Antiviral Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1089\/vim.2005.18.558","article-title":"Neutralizing Monoclonal Antibodies Against Russian Strain of the West Nile Virus","volume":"18","author":"Razumov","year":"2005","journal-title":"Viral Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/s41596-024-01079-8","article-title":"Biolayer interferometry for measuring the kinetics of protein\u2013protein interactions and nanobody binding","volume":"20","author":"Bates","year":"2025","journal-title":"Nat. Protoc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"117741","DOI":"10.1016\/j.trac.2024.117741","article-title":"Biolayer interferometry and its applications in drug discovery and development","volume":"176","author":"Jug","year":"2024","journal-title":"Trends Anal. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kulemzin, S.V., Sergeeva, M.V., Baranov, K.O., Gorchakov, A.A., Guselnikov, S.V., Be-lovezhets, T.N., Volkova, O.Y., Najakshin, A.M., Chikaev, N.A., and Danilenko, D.M. (2022). VH3-53\/66-Class RBD-Specific Human Monoclonal Antibody iB20 Displays Cross-Neutralizing Activity against Emerging SARS-CoV-2 Lineages. J. Pers. Med., 12.","DOI":"10.3390\/jpm12060895"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Liu, R., Oldham, R.J., Teal, E., Beers, S.A., and Cragg, M.S. (2020). Fc-engineering for modulated effector functions\u2014Improving antibodies for cancer treatment. Antibodies, 9.","DOI":"10.3390\/antib9040064"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kalinichenko, S.V., Ramadan, L., Kruglova, N.A., Balagurov, K.I., Lukashina, M.I., Mazurov, D.V., and Shepelev, M.V. (2024). A New Chimeric Antibody against the HIV-1 Fusion Inhibitory Peptide MT-C34 with a High Affinity and Fc-Mediated Cellular Cytotoxicity. Biology, 13.","DOI":"10.3390\/biology13090675"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41573-022-00495-3","article-title":"Antibodies to combat viral infections: Development strategies and progress","volume":"21","author":"Pantaleo","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.4049\/jimmunol.170.7.3528","article-title":"The MHC Class I-Like IgG Receptor Controls Perinatal IgG Transport, IgG Homeostasis, and Fate of IgG-Fc-Coupled Drugs","volume":"170","author":"Roopenian","year":"2003","journal-title":"J. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6982","DOI":"10.1128\/JVI.00551-06","article-title":"Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus","volume":"80","author":"Throsby","year":"2006","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"12766","DOI":"10.1128\/JVI.01420-07","article-title":"Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody","volume":"81","author":"Lai","year":"2007","journal-title":"J. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1128\/JVI.00291-08","article-title":"Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo","volume":"82","author":"Goncalvez","year":"2008","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cell.2016.07.020","article-title":"Structural Basis of Zika Virus-Specific Antibody Protection","volume":"166","author":"Zhao","year":"2016","journal-title":"Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1002\/jps.24444","article-title":"Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins","volume":"104","author":"Liu","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/btpr.2498","article-title":"Impact of IgG fc-oligosaccharides on recombinant monoclonal antibody structure, stability, safety, and efficacy","volume":"33","author":"Liu","year":"2017","journal-title":"Biotechnol. Prog."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/glycob\/cwv065","article-title":"Fc glycans of therapeutic antibodies as critical quality attributes","volume":"12","author":"Reusch","year":"2015","journal-title":"Glycobiology"},{"key":"ref_38","unstructured":"Nesmeyanova, V.S., Shanshin, D.V., Isaeva, A.A., and Protopopova, E.V. (2023). pVEAL2-9E2ch-scFv Plasmid Genetic Construct, Strain of Recombinant Cell Line CHO-K1-9E2ch and Chimeric Single-Chain Antibody 9E2ch Against West Nile Virus Produced by the Specified Strain of Cell Line CHO-K1-9E2ch, with High Affinity for Neonatal FcRn Receptor. (Patent RU 2 801 532 C1)."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Svyatchenko, V.A., Ternovoi, V.A., Lutkovskiy, R.Y., Protopopova, E.V., Gudymo, A.S., Danilchenko, N.V., Susloparov, I.M., Kolosova, N.P., Ryzhikov, A.B., and Taranov, O.S. (2023). Human Adenovirus and Influenza A Virus Exacerbate SARS-CoV-2 Infection in Animal Models. Microorganisms, 11.","DOI":"10.3390\/microorganisms11010180"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/24\/12181\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:32:23Z","timestamp":1766068343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/24\/12181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,18]]},"references-count":39,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["ijms262412181"],"URL":"https:\/\/doi.org\/10.3390\/ijms262412181","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,18]]}}}